Skip to main content
Clinical Trials/JPRN-UMIN000003751
JPRN-UMIN000003751Not yet recruitingPhase 2

A phase II feasibility trial of Gemcitabine Hydrochloride and Krestin combination therapy in pancreatic cancer after surgery. - A phase II feasibility trial of Gemcitabine Hydrochloride and Krestin combination therapy in pancreatic cancer after surgery.

Kyoto University Hospital0 sites20 target enrollmentStarted: June 30, 2010Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to 80years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1)Active double cancer. 2)Patients with severe myelosuppression. 3)Patients who receiving radiation therapy to the chest. 4)Patients with severe infection. 5)Patients with pulmonary fibrosis or interstitial lung disease. 6)Pregnant patients. 7)Patients with insanity or psychological symptom.

Investigators

Similar Trials